TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03822104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FM85
Description: Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
Study: NCT02333084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRN Joint Health Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PRN Flex Omega Benefits® combination
Study: NCT02200510

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management intervention for Adolescents with SCD
Description: Chronic Disease Self-Management Program
Study: NCT02200510

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Portal Intervention for Adolescents with SCD
Description: MyChart for SCD intervention
Study: NCT04454632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: affected arm stay behind the mirror while exercising

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual feedback
Description: visual feedback from mirror
Study: NCT04692285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809
Study: NCT01667159

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
Study: NCT04158206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal voice
Description: Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
Study: NCT04692285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
Study: NCT02929056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AmnioExCel dressing and compression therapy
Description: Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809
Study: NCT02929056

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SOC alginate dressing and compression therapy
Description: Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
Study: NCT00805675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg monotherapy supplied in film-coated tablets.
Study: NCT03677752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GP_Posit
Description: Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809
Study: NCT00815373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide+Timolol Maleate0.5%
Description: Cosopt\* b. i. d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost+Timolol Maleate0.5%+Lytears
Description: Xalacom\* QHS
Study: NCT01959087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single port surgery
Description: Single port surgery can be converted in multiport surgery if necessary

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiport surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiport surgery
Study: NCT01281592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOR-253 HCl
Description: LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
Study: NCT01480193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound Based and Educational Therapies
Description: The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound Based and Educational Therapies
Description: The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to MK1809
Study: NCT02399514

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnographic diagnostic
Description: Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
Study: NCT03443427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi Mcat investigational vaccine (GSK3277511A)
Description: Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi Mcat investigational vaccine (GSK3277511A)
Description: Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
Study: NCT00599638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: 75mg bid titrating to 150mg bid on day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin/PF-00489791
Description: Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02209623

Intervention type: BIOLOGICAL
Intervention: TDAP
Study: NCT01435837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2 (200mg of caffeine; 1/2 L of water)
Description: 200mg of caffeine (tablet); 1/2 of water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C2 (200mg of caffeine; 1/2 L of water)
Description: 200mg of caffeine (tablet); 1/2 of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C3(200mg of caffeine; 1 L of water)
Description: Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C3(200mg of caffeine; 1 L of water)
Description: Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 (200mg of caffeine, no water)
Description: Ingestion of 200mg of caffeine (tablet); no water ingestion.
Study: NCT02717208

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HL036
Study: NCT00805675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir disoproxil fumarate was supplied in 300 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine plus tenofovir
Description: Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
Study: NCT05500950

Intervention type: OTHER
Intervention: CDU and CT-DCG or CT examination
Description: patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
Study: NCT01435837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C1 (200mg of caffeine, no water)
Description: Ingestion of 200mg of caffeine (tablet); no water ingestion.
Study: NCT03676322

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049.
Study: NCT03739112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine
Description: Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent® Comparator Vaccine
Description: Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
Study: NCT01047956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone; NAC
Description: Methadone NAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone
Study: NCT02618434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (18 mg)
Description: Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (36 mg)
Description: Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study: NCT01435837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (no caffeine, no water).
Description: No ingestion of caffeine; no ingestion of water between pretest and posttest.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (no caffeine, no water).
Description: No ingestion of caffeine; no ingestion of water between pretest and posttest.
Study: NCT03959202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELDERFITNESS
Description: In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
Study: NCT01480193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Therapies and Sound Based Education Therapies
Description: 3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
Study: NCT00954356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
Study: NCT02717208

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HL036

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Study: NCT01257724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHARE (Synthesized HIV/AIDS Research Evidence)
Description: SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHARE (Synthesized HIV/AIDS Research Evidence)
Description: SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence
Study: NCT02214095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucosamine sulphate
Description: group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose capsules
Study: NCT02984371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epicardial ganglionated plexi ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantable loop recorder

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantable loop recorder
Study: NCT02768753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Axillary Bilateral-breast Approach
Study: NCT02626117

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER deepithelialization
Description: the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
Study: NCT02768753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The bilateral Axillo-breast Approach
Study: NCT04080323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: 1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 vaginal tablet of placebo 60 minutes before surgery
Study: NCT03329261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: COPIGREL® - clopidogrel dosed at 75 mg per tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: COPIGREL® - clopidogrel dosed at 75 mg per tablet
Study: NCT01987583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet cupping
Description: Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
Study: NCT02626117

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LASER deepithelialization
Description: the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
Study: NCT01987583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
Study: NCT04415632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low glycemic index diet
Description: • Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: High glycemic index diet
Description: Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.